Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A

Cocrystal Pharma, Inc.

Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
Guidance clarifies regulatory requirements for planned Phase 2b trial design.
Phase 2a challenge study in UK ongoing; topline results expected H2 2024.
Preparations underway for inhaled CC-42344 Phase 1 study in Australia.
Inhaled formulation showed superior lung exposure and favorable safety in preclinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.